Loading...
Seralutinib Will Succeed As Aging Populations Drive PAH Demand
AnalystHighTarget's Fair Value
US$15.00
82.9% undervalued intrinsic discount10 Sep
US$2.56
1Y
160.2%7D
3.2%1Y
160.2%7D
3.2%You can edit this narrative until Aug 10 10:24 PM. Then, changes will post as Updates.